CNS Therapeutics

CNS Therapeutics


Global CNS Therapeutics Market to Reach US$199.0 Billion by 2030

The global market for CNS Therapeutics estimated at US$122.0 Billion in the year 2023, is expected to reach US$199.0 Billion by 2030, growing at a CAGR of 7.2% over the analysis period 2023-2030. Neurodegenerative Diseases Therapeutics, one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$75.9 Billion by the end of the analysis period. Growth in the Mental Health Therapeutics segment is estimated at 7.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$49.2 Billion While China is Forecast to Grow at 11.3% CAGR

The CNS Therapeutics market in the U.S. is estimated at US$49.2 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$19.9 Billion by the year 2030 trailing a CAGR of 11.3% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.5% and 6.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.2% CAGR.

Global CNS Therapeutics Market - Key Trends & Drivers Summarized

Central Nervous System (CNS) therapeutics encompass a broad range of treatments aimed at addressing disorders and diseases of the brain and spinal cord. These include conditions such as Alzheimer`s disease, Parkinson`s disease, epilepsy, depression, and multiple sclerosis. CNS therapeutics comprise pharmaceuticals, biologics, and advanced therapies like gene and cell therapies. The complexity of the CNS and the blood-brain barrier poses significant challenges in developing effective treatments, but advances in neuroscience, molecular biology, and drug delivery systems are leading to innovative therapeutic approaches. Precision medicine and personalized treatments are becoming increasingly important in CNS therapeutics, offering the potential for more targeted and effective interventions.

The market for CNS therapeutics is driven by the high prevalence of neurological and psychiatric disorders, which significantly impact the quality of life and healthcare systems worldwide. An aging population is contributing to the rising incidence of neurodegenerative diseases like Alzheimer`s and Parkinson`s. Additionally, increased awareness and better diagnostic capabilities are leading to earlier detection and treatment of CNS conditions. The pharmaceutical industry is heavily invested in CNS research and development, resulting in a robust pipeline of new drugs and therapies. Regulatory agencies are also prioritizing the approval of innovative treatments for CNS disorders, recognizing the urgent need for effective solutions.

The growth in the CNS therapeutics market is driven by several factors. Firstly, the increasing prevalence of neurological and psychiatric disorders due to aging populations and improved diagnostics is boosting demand for CNS treatments. Secondly, significant advancements in neuroscience research and drug development are leading to new and more effective therapeutic options. Thirdly, the growing emphasis on precision medicine and personalized therapies is enhancing treatment efficacy and patient outcomes. Lastly, supportive regulatory environments and the prioritization of CNS disorder treatments are accelerating the approval and commercialization of new therapies. These factors collectively contribute to the dynamic growth of the CNS therapeutics market.

Select Competitors (Total 353 Featured) -
  • Abbott Laboratories, Inc.
  • AbbVie, Inc.
  • Acumen Pharmaceuticals, Inc.
  • Alexza Pharmaceuticals
  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • AC Immune SA
  • Addex Therapeutics
  • Ache Laboratorios Farmaceuticos SA
  • 4D pharma plc
  • Acadia Pharmaceuticals, Inc.
  • AB Science SA
  • ABL Bio, Inc.
  • AcelRx Pharmaceuticals
  • Aarti Drugs Ltd.
  • Abion
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Central Nervous System (CNS) Therapeutics: A Prelude
Global Central Nervous System Therapeutic Market Glimmers with Robust Health
Patent Expiries of Major Drugs Exert Downward Pressure on the Global CNS Market
Developed Markets to Maintain their Dominance
Developing Market to Drive the Market Momentum, Asia-Pacific to Exhibit Fastest Growth
Neurodegenerative Disease & Mental Health: Lifeline Segments of CNS Therapeutics Market
CNS Cancer Segment to Post Fastest Growth
Competition
CNS Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
Recent Market Activity
MARKET ANALYSIS BY THERAPEUTIC CATEGORY
Anti-Epilepsy Market
Regional Landscape
Developed Countries Account for a Major Share of Epilepsy Treatment
Developing Countries Struggle with Low Treatment Rates
Disease Overview
Epilepsy Incidence by Type (2022E): Percentage Share Breakdown for Idiopathic and Symptomatic Epilepsy
Symptomatic Epilepsy Incidence by Type (2022E): Percentage Share Breakdown of Congenital, Degenerative, Infective, Neoplastic, Trauma, and Vascular Epilepsy
Global Epilepsy Etiology: Percentage Breakdown by Type for 2022E
Drugs for Epilepsy
Market for Epilepsy Drugs
Regional Landscape
Developing Countries Struggle with Low Treatment Rates
High Unmet Needs Offer Scope for Market Growth
Treatment
Anti-Epileptic Drugs (AEDs) by Generic Name and Brand Names
Leading Anti-Epileptic Drugs
Leading Anti-Epileptic Drugs and Their Mechanism of Action
Patent Expiries of Major Anti-Epilepsy Drugs
FDA's New Policy for AED Drugs to Bolster Market Growth
AAN Updated Guidelines on New AEDs Use for Treating New Onset Epilepsy (2019)
Select Currently Available Epilepsy Drugs
Innovative Drugs Needed for Better Treatment Compliance
Abounding Potential for NCEs
A New Research Demonstrates Effectiveness of Gluconate in Treating Neonatal Seizures
FDA Approves Epidiolex (Cannabidiol) - First Drug for Treating Dravet Syndrome and Lennox-Gastaut Syndrome
Refractory Childhood Epilepsy & Pregnancy Epilepsy - Major Concerns
Recent Approvals for Childhood Epilepsy
Review of Anti-Epilepsy Drugs
Vimpat(r)
Keppra(r)
Lamictal
Tegretol(r)
Sabril(r)
Perampanel
Zonegran(r)
Topamax(r)
Trileptal(r)
Neurontin(r)
Lyrica(r)
Depakine(r)
Anti-Alzheimer's
Market Overview
Global Alzheimer's Prevalence by Age Group
Alzheimer's Phase III Completed Studies
Alzheimer's Phase III Ongoing Studies
Treatment for Alzheimer's
Select Leading Drugs for Alzheimer's Disease by Drug Category
Patent Expiries of Leading Alzheimer's Drugs
Alzheimer's Drugs: A Market Plagued with Failures
Promising Compounds with Silver Lining
Updated FDA Standards Make Way for Increased Alzheimer's Drug Testing
Rising Discontinuation of BACE Programs for Alzheimer's to Dampen Market Growth
Rising Discontinuation of BACE Programs for Alzheimer's to Dampen Market Growth
Novel Drug Delivery Method to the Brain Discovered
Alzheimer's Association Provides Grant to Longeveron
A Review of Select Anti-Alzheimer's Drugs
Aricept
Exelon
Reminyl
Ebixa
Namenda
A Review of the Alzheimer's disease
Alzheimer's Effect on Brain
Causes for Alzheimer's
Who Are at Risk?
Prevalence of Alzheimer's Disease
Diagnosis of Alzheimer's
Anti-Parkinson's
Market Overview
Nourianz, An Add-on Medication for Treating Episodes of Parkinson's Disease Secures FDA Approval
Recent Approvals
Novel Drug and a New Delivery Method for Restoring Brain Cells in People Suffering from PD
Xadago - Add-On Therapy for Parkinson's Disease
NUPLAZID(r) - The First and the Only Approved Drug for Psychosis related to Parkinson's disease
Select Parkinson's Phase III Completed Studies: As of June 2022
Select Parkinson's Ongoing Phase III Studies: As of June 2022
Select Anti-Parkinson's Drugs
Levodopa
Dopamine Agonists
Mirapex
GSK Discontinues Requip for PD and RSL Treatment
A Review of the Parkinson's Disease
Prevalence
Symptoms
Causes
Diagnosis
Anti-Depressants
Market Overview
Anti-Depressant Market: Percentage Share Breakdown by Depressive Disorder Type
Anti-Depressant Treatment
Select Antidepressants Drugs
Zoloft (Sertraline)
Cymbalta(r)
Prozac (Fluoxetine)
Effexor (Venlafaxine)
Paxil
Wellbutrin (Bupropion)
Select Pipeline Drugs in Phase III for Depressive Disorders: As of June 2022
A Review of Depression
Prevalence of Depression
Causes of Depression
Types of Depressive Disorders
Available Treatment
Tricyclic Antidepressants
Monoamine Oxidase Inhibitors
Lithium Salts
Working of Antidepressants
Ranking of Antidepressants in Terms of Efficacy
Types of Antidepressants
NMDA Receptor Antagonists
NMDA Receptor (NMDAR)
NMDA Receptor Agonists
Acetylcholinesterase Inhibitors
Selective Serotonin Reuptake Inhibitors (SSRIs)
Workings of SSRIs
Safety Levels of SSRI Drugs
Adverse Effects of SSRI
Serotonin Noradrenaline Reuptake Inhibitors (SNRIs)
Other CNS Disorders (Multiple Sclerosis, Attention Deficit Hyperactivity Disorder (ADHD), and Insomnia)
Multiple Sclerosis (MS)
List of Approved Drugs for MS
Patent Expiration Date/Year of the Major MS Drugs
New Approvals
Novartis Receives FDA Approval for Mayzent for Use in Multiple Sclerosis
Mavenclad Gains FDA Approval
Celgene Files NDA for Ozanimod
Ocrevus - The First Approved Drug for Primary Progressive Multiple Sclerosis (PPMS)
Multiple Sclerosis: Pipeline Analysis
Select Pipeline Drugs in Phase III for Multiple Sclerosis: As of June 2022
A Review of Multiple Sclerosis (MS)
Types of Multiple Sclerosis
Clinical Subtypes of Multiple Sclerosis (MS)
Prevalence of MS
Causes of MS
Myths Surrounding Multiple Sclerosis
Symptoms of MS
Diagnosis of MS
Insomnia
Overview
List of Approved Drugs for Insomnia
Select Pipeline Drugs for Insomnia: As of June 2022
Zolpidem
Eszopiclone
A Review of Insomnia
Prevalence of Insomnia
Therapies for Insomnia
CNS Pain Management
Market Overview
Treatment
Drugs Indicated for Pain Management
Regional Overview
Players
Combination Therapies Gain Prominence
Key Trends in Chronic Pain Management
Neuropathic Pain Management: Market with High Potential
Select Phase III Ongoing Studies for Neuropathic Pain
Lyrica's Generics Gain FDA Approval
Migraine Market: A Core Vertical in CNS Pain Management
Migraine Care: Select Patent Expiries (2013-2015)
Migraine Completed Phase III Studies
Migraine Ongoing Phase III Studies
Select Pain Management Drugs
Flupirtine
Lyrica
Oxycodone
Nucynta ER
Metabotropic Glutamate Receptors (mGluRs)
New Pain Management Drugs
Novartis Presents New Data for Aimovig
Reyvow, Eli Lilly's Novel Migraine Drug with the Potential to Lead the Global Migraine Medications Market
Three New Migraine Drugs Obtain FDA Approval
Eli Lilly's Emgality Receives FDA Approval
An Insight into Mental Health Prevalence and Addressal
Global Prevalence of Mental Health Disorders by Type
Anti-Psychotics
Market Overview
Leading Atypical Antipsychotics for the Treatment of Schizophrenia
Select Pipeline Drugs in Phase III for Schizophrenia: As of June 2022
Select Pipeline Drugs in Phase III for Bipolar Disorder: As of June 2022
Select Anti-Psychotic Drugs
Zyprexa
Seroquel
Abilify
Clozaril
Risperdal
Risperdal(r) Consta(r)
Geodon
Invega Sustenna
Saphris
Latuda
A Review of Anti-Psychotics
Indications of Antipsychotics
An Effective Adjunctive Therapy
Off-label Uses
Efficacy - Marred by Lack of Evidence Base
Types of Antipsychotics
Difference between Typical and Atypical
Atypical Antipsychotics Up Against Typicals
Side Effects of Antipsychotics
Symptoms of Antipsychotics Withdrawal
Bipolar Disorder
Symptoms of Bipolar Disorder
Mood Episode - A Major Symptom
Manic Episode Vs Depressive Episode
Causes of Bipolar Disorder
Types of Bipolar Disorder
Co-morbidities of Bipolar Disorder
Schizophrenia
Prevalence by Gender
Symptoms of Schizophrenia
Causes of Schizophrenia
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Incidence of Neurodegenerative Conditions
Burgeoning Global Aging Populace, Longer Life Expectancy to Drive CNS Demand
Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
Increased Spending on Prescription Drugs Bodes Well for the CNS Therapeutics Market
Rising Healthcare Expenditure to Boost CNS Therapeutics Market
World Healthcare Expenditure (In US$ Trillion) for the Years 2017, 2019, 2021 & 2023
Per Capita Healthcare Expenditure (in $) by Select Countries for 2018
Growing Middle Class Population in Emerging Regions to Spur the Market
Global Middle Class Population (In Million) by Region for the Years 2020, 2025 and 2030
Global Middle Class Spending (US$ Trillion) by Region for the Years 2020, 2025, 2030
Developments in CNS Drug Delivery Technologies Bode Well for the CNS Drugs Market
Understanding of BBB Cell Biology & Its Positive Impact on Epilepsy Drugs: A Case-in-Point
Pharma Companies: Seeking New Tools to Offset Pressure on Drug Pipelines
Awareness Campaigns Launched by Pharma Companies to Benefit the Market...
Music and Memory Programs Positively Impact Alzheimer's Disease (AD) and Related Dementia (ADRD) Patients
New Method to Isolate Active Compounds Related to Alzheimers from Plant Medicines
Influx of New Products & Strong Pipeline
CNS Pharmaceuticals Secures FDA Approval for Protocol Amendment to Trial Targeting GBM Treatment
Central Nervous System Therapeutics: From Bleak to Bright Outlook
Novel Drug-Delivery Options
Advances in Drug Discovery Methods for Rare Diseases
Market Restraint: Complex Nature of R&D
Ongoing Research on Psychedelics Substances Pave Way for Ensuring Timely Treatment for Various Mental Illnesses
Advent of Advanced Disease Pathology and Diagnostics Techniques Facilitate Medical Professionals in Diagnosing Mental Illness at an Earlier Stage
Introduction of Innovative Technologies Fuel Demand for Biological Medicines
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World CNS Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for CNS Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 3: World Historic Review for CNS Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 4: World 16-Year Perspective for CNS Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Neurodegenerative Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 6: World Historic Review for Neurodegenerative Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 7: World 16-Year Perspective for Neurodegenerative Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Mental Health by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 9: World Historic Review for Mental Health by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 10: World 16-Year Perspective for Mental Health by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Neurovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 12: World Historic Review for Neurovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 13: World 16-Year Perspective for Neurovascular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Cns Trauma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 15: World Historic Review for Cns Trauma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 16: World 16-Year Perspective for Cns Trauma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 18: World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 19: World 16-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Cns Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 21: World Historic Review for Cns Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 22: World 16-Year Perspective for Cns Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 24: World Historic Review for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 25: World 16-Year Perspective for Other Segments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
Market Facts & Figures
Aging Population: A Strong Demographic Driver
North American Elderly Population by Age Group (1975-2050)
The Largest CNS Therapeutics Market Globally
Patent Expiries of Leading CNS Drugs in the US
Focus on Select Markets
Alzheimer's Market
Anti-depressant Drugs
Usage of Antidepressants Surges in the US
Anti-Epilepsy Market
Epilepsy - A Major Concern for the Healthcare Industry
A Glance at Epilepsy Statistics
Anti-Epilepsy Drugs
The US Epilepsy Market: Patent Expiry of Select Major Drugs
Epilepsy in Children
Growing Competition from Generics
Pain Management Market
Consumers in the US Seek Different Options for Chronic Pain Management
Neuropathic Pain Market
Anti-Psychotic Drugs Market
Mental Illnesses - Epidemiology
Facts & Figures
Lifetime Prevalence (%) of Bipolar Disorder in the US Population by Age Group
Popular Antipsychotic Drugs in the US
The US Anti-Psychotic Drugs Market by Indication (2022E): Percentage Share Breakdown of Value Sales
Surging Off-label Prescriptions
Generics Occupy Front Seat
Rising Antipsychotic Use among Children - A Cause of Concern
Market Analytics
Market Analytics
TABLE 26: USA Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 27: USA Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 28: USA 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
CANADA
CNS Diseases: Facts & Figures
TABLE 29: Canada Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 30: Canada Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 31: Canada 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
JAPAN
TABLE 32: Japan Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 33: Japan Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 34: Japan 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
CHINA
China: The Primary Market for CNS Drugs in Asia-Pacific
Select Anti-Schizophrenia Drugs Available in China
Other Available CNS Drugs in China
TABLE 35: China Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 36: China Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 37: China 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
EUROPE
Market Facts & Figures
Pain Management Market
Neuropathic Pain Market Witnesses Foray of Generics
Anti-Psychotics Market
Demand for Antipsychotics for Bipolar Disorder Upbeat
Market Analytics
TABLE 38: Europe Recent Past, Current & Future Analysis for CNS Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 39: Europe Historic Review for CNS Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 40: Europe 16-Year Perspective for CNS Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 41: Europe Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 42: Europe Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 43: Europe 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
FRANCE
TABLE 44: France Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 45: France Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 46: France 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
GERMANY
TABLE 47: Germany Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 48: Germany Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 49: Germany 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
ITALY
Market Snapshots
TABLE 50: Italy Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 51: Italy Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 52: Italy 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
UNITED KINGDOM
NICE Recommendations on CNS Therapeutics
TABLE 53: UK Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 54: UK Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 55: UK 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
SPAIN
TABLE 56: Spain Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 57: Spain Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 58: Spain 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
RUSSIA
TABLE 59: Russia Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 60: Russia Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 61: Russia 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 62: Rest of Europe Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 63: Rest of Europe Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 64: Rest of Europe 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
ASIA-PACIFIC
India & China Offer Significant Growth Opportunities
Growing Antipsychotics Market in Asia
TABLE 65: Asia-Pacific Recent Past, Current & Future Analysis for CNS Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 66: Asia-Pacific Historic Review for CNS Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 67: Asia-Pacific 16-Year Perspective for CNS Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
TABLE 68: Asia-Pacific Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 69: Asia-Pacific Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 70: Asia-Pacific 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
AUSTRALIA
TABLE 71: Australia Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 72: Australia Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 73: Australia 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
INDIA
TABLE 74: India Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 75: India Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 76: India 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
SOUTH KOREA
TABLE 77: South Korea Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 78: South Korea Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 79: South Korea 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
REST OF ASIA-PACIFIC
TABLE 80: Rest of Asia-Pacific Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 81: Rest of Asia-Pacific Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 82: Rest of Asia-Pacific 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
LATIN AMERICA
TABLE 83: Latin America Recent Past, Current & Future Analysis for CNS Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 84: Latin America Historic Review for CNS Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 85: Latin America 16-Year Perspective for CNS Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
TABLE 86: Latin America Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 87: Latin America Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 88: Latin America 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
ARGENTINA
TABLE 89: Argentina Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 90: Argentina Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 91: Argentina 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
BRAZIL
TABLE 92: Brazil Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 93: Brazil Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 94: Brazil 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
MEXICO
TABLE 95: Mexico Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 96: Mexico Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 97: Mexico 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
REST OF LATIN AMERICA
TABLE 98: Rest of Latin America Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 99: Rest of Latin America Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 100: Rest of Latin America 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
MIDDLE EAST
TABLE 101: Middle East Recent Past, Current & Future Analysis for CNS Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 102: Middle East Historic Review for CNS Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 103: Middle East 16-Year Perspective for CNS Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
TABLE 104: Middle East Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 105: Middle East Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 106: Middle East 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
IRAN
TABLE 107: Iran Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 108: Iran Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 109: Iran 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
ISRAEL
TABLE 110: Israel Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 111: Israel Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 112: Israel 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
SAUDI ARABIA
TABLE 113: Saudi Arabia Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 114: Saudi Arabia Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 115: Saudi Arabia 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
UNITED ARAB EMIRATES
TABLE 116: UAE Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 117: UAE Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 118: UAE 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
REST OF MIDDLE EAST
TABLE 119: Rest of Middle East Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 120: Rest of Middle East Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 121: Rest of Middle East 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
AFRICA
TABLE 122: Africa Recent Past, Current & Future Analysis for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 123: Africa Historic Review for CNS Therapeutics by Segment - Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 124: Africa 16-Year Perspective for CNS Therapeutics by Segment - Percentage Breakdown of Value Sales for Neurodegenerative Diseases, Mental Health, Neurovascular Diseases, Cns Trauma, Infectious Diseases, Cns Cancer and Other Segments for the Years 2014, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings